Whitehawk Therapeutics (WHWK) CFO receives 38,265-share stock award

Rhea-AI Filing Summary

Whitehawk Therapeutics, Inc. Chief Financial Officer Scott M. Giacobello reported a compensation-related stock award on a Form 4. He acquired 38,265 shares of common stock on May 14, 2026 in a transaction classified as a grant or award at a reference price of $3.92 per share. Following this award, his directly held ownership increased to 333,489 shares of Whitehawk Therapeutics common stock. This filing reflects an equity grant rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Giacobello Scott M.

Role CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	38,265	$3.92	$150K

Holdings After Transaction: Common Stock — 333,489 shares (Direct, null)

Footnotes (1)

Key Figures

Shares granted: 38,265 shares Reference share price: $3.92 per share Post-transaction holdings: 333,489 shares

3 metrics

Shares granted 38,265 shares Common Stock award on May 14, 2026

Reference share price $3.92 per share Reported transaction price for granted shares

Post-transaction holdings 333,489 shares CFO direct ownership after grant

Key Terms

Grant, award, or other acquisition, Common Stock, Form 4, Chief Financial Officer

4 terms

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Chief Financial Officer financial

"officer_title: CHIEF FINANCIAL OFFICER"

A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Giacobello Scott M.

(Last) (First) (Middle)

C/O WHITEHAWK THERAPEUTICS, INC.

2 HEADQUARTERS PLAZA, EAST BUILDING, 11T

(Street)

MORRISTOWN NEW JERSEY 07960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Whitehawk Therapeutics, Inc. [ WHWK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/14/2026		A		38,265	A	$3.92	333,489	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Stephen Rodin, as Attorney-in-Fact	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did WHWK CFO Scott M. Giacobello report?

Whitehawk Therapeutics CFO Scott M. Giacobello reported receiving a grant of 38,265 shares of common stock. The Form 4 classifies this as a grant or award acquisition, reflecting equity compensation rather than an open-market trade by the executive.

How many Whitehawk Therapeutics (WHWK) shares did the CFO receive in this Form 4?

The CFO received 38,265 shares of Whitehawk Therapeutics common stock. The transaction is coded as an acquisition via grant or award, indicating it is part of his compensation package instead of a discretionary market purchase of the company’s shares.

At what price is the WHWK CFO’s awarded stock reported on the Form 4?

The awarded shares are reported at a price of $3.92 per share. This figure represents the reference price used in the filing for the 38,265 granted shares, not a confirmed open-market purchase price set by the executive.

What is the CFO’s total WHWK share ownership after this transaction?

After the grant, the CFO’s direct ownership is reported as 333,489 shares. This total reflects his holdings of Whitehawk Therapeutics common stock immediately following the 38,265-share award disclosed in the Form 4 filing.

Was the WHWK CFO’s Form 4 transaction a market buy or a compensation grant?

The transaction is a compensation grant, not an open-market buy. The Form 4 uses code A, described as a grant, award, or other acquisition, showing the CFO received shares as part of his equity compensation plan.